Inhibition of Cerebral Vascular Inflammation by Brain Endothelium-targeted Oligodeoxynucleotide Complex

Overview

Journal Neuroscience

Specialty Neurology

Date 2016 May 2

PMID 27132231

Citations 4

Authors

Jing Hu

Daniah Al-Waili

Aishlin Hassan

Guo-Chang Fan

Mei Xin

JiuKuan Hao

Affiliations

Soon will be listed here.

Abstract

The present study generated a novel DNA complex to specifically target endothelial NF-κB to inhibit cerebral vascular inflammation. This DNA complex (GS24-NFκB) contains a DNA decoy which inhibits NF-κB activity, and a DNA aptamer (GS-24), a ligand of transferrin receptor (TfR), which allows for targeted delivery of the DNA decoy into cells. The results indicate that GS24-NFκB was successfully delivered into a murine brain-derived endothelial cell line, bEND5, and inhibited inflammatory responses induced by tumor necrosis factor α (TNF-α) or oxygen-glucose deprivation/re-oxygenation (OGD/R) via down-regulation of the nuclear NF-κB subunit, p65, as well as its downstream inflammatory cytokines, inter-cellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule (VCAM-1). The inhibitory effect of the GS24-NFκB was demonstrated by a significant reduction in TNF-α or OGD/R induced monocyte adhesion to the bEND5 cells after GS24-NFκB treatment. Intravenous (i.v.) injection of GS24-'NFκB (15mg/kg) was able to inhibit the levels of phoseph-p65 and VCAM-1 in brain endothelial cells in a mouse lipopolysaccharide (LPS)-induced inflammatory model in vivo. In conclusion, our approach using DNA nanotechnology for DNA decoy delivery could potentially be utilized for inhibition of inflammation in ischemic stroke and other neuro-inflammatory diseases affecting cerebral vasculature.

Citing Articles

Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges.

Kong A, Wu A, Ho O, Leung M, Huang A, Yu Y Int J Mol Sci. 2023; 24(14).

PMID: 37511539 PMC: 10380291. DOI: 10.3390/ijms241411780.

Targeting vascular inflammation through emerging methods and drug carriers.

Nong J, Glassman P, Muzykantov V Adv Drug Deliv Rev. 2022; 184:114180.

PMID: 35271986 PMC: 9035126. DOI: 10.1016/j.addr.2022.114180.

Beneficial Effects of Inflammatory Cytokine-Targeting Aptamers in an Animal Model of Chronic Prostatitis.

Ho D, Chang P, Lin W, Huang Y, Lin J, Huang K Int J Mol Sci. 2020; 21(11).

PMID: 32486412 PMC: 7312664. DOI: 10.3390/ijms21113953.

Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches.

Shekhar S, Cunningham M, Pabbidi M, Wang S, Booz G, Fan F Eur J Pharmacol. 2018; 833:531-544.

PMID: 29935175 PMC: 6090562. DOI: 10.1016/j.ejphar.2018.06.028.

References

Dufes C, Al Robaian M, Somani S . Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther Deliv. 2013; 4(5):629-40. DOI: 10.4155/tde.13.21. View

JACOBS M, Harrison S . Structure of an IkappaBalpha/NF-kappaB complex. Cell. 1998; 95(6):749-58. DOI: 10.1016/s0092-8674(00)81698-0. View

Laflamme N, Lacroix S, Rivest S . An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J Neurosci. 1999; 19(24):10923-30. PMC: 6784955. View

Wang X, Qin Z, Shi H, Savitz S, Qin A, Jiang Y . Protective effect of Ginkgolids (A+B) is associated with inhibition of NIK/IKK/IkappaB/NF-kappaB signaling pathway in a rat model of permanent focal cerebral ischemia. Brain Res. 2008; 1234:8-15. DOI: 10.1016/j.brainres.2008.07.102. View

Baldwin Jr A . Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest. 2001; 107(1):3-6. PMC: 198555. DOI: 10.1172/JCI11891. View

Lindsberg P, Carpen O, Paetau A, Karjalainen-Lindsberg M, Kaste M . Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation. 1996; 94(5):939-45. DOI: 10.1161/01.cir.94.5.939. View

Kooij G, van Horssen J, de Lange E, Reijerkerk A, van der Pol S, van Het Hof B . T lymphocytes impair P-glycoprotein function during neuroinflammation. J Autoimmun. 2009; 34(4):416-25. DOI: 10.1016/j.jaut.2009.10.006. View

Zhang Y, Pardridge W . Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 2001; 889(1-2):49-56. DOI: 10.1016/s0006-8993(00)03108-5. View

Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A . In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med. 1997; 3(8):894-9. DOI: 10.1038/nm0897-894. View

10.

DAcquisto F, Ianaro A, Ialenti A, Maffia P, Maiuri M, Carnuccio R . Transcription factor decoy oligodeoxynucleotides to nuclear factor-kappaB inhibit reverse passive Arthus reaction in rat. Naunyn Schmiedebergs Arch Pharmacol. 2001; 364(5):422-9. DOI: 10.1007/s002100100472. View

11.

Yang G, Gong C, Qin Z, Liu X, Betz A . Tumor necrosis factor alpha expression produces increased blood-brain barrier permeability following temporary focal cerebral ischemia in mice. Brain Res Mol Brain Res. 1999; 69(1):135-43. DOI: 10.1016/s0169-328x(99)00007-8. View

12.

Xu L, Zhan Y, Wang Y, Feuerstein G, Wang X . Recombinant adenoviral expression of dominant negative IkappaBalpha protects brain from cerebral ischemic injury. Biochem Biophys Res Commun. 2002; 299(1):14-7. DOI: 10.1016/s0006-291x(02)02573-1. View

13.

Zhang Y, Boado R, Pardridge W . Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res. 2003; 20(11):1779-85. DOI: 10.1023/b:pham.0000003375.13655.f9. View

14.

Tomita N, Morishita R, Tomita S, Kaneda Y, Higaki J, Ogihara T . Inhibition of TNF-alpha, induced cytokine and adhesion molecule. Expression in glomerular cells in vitro and in vivo by transcription factor decoy for NFkappaB. Exp Nephrol. 2001; 9(3):181-90. DOI: 10.1159/000052610. View

15.

Xu J, Wu Y, He L, Yang Y, Moore S, Hsu C . Regulation of cytokine-induced iNOS expression by a hairpin oligonucleotide in murine cerebral endothelial cells. Biochem Biophys Res Commun. 1997; 235(2):394-7. DOI: 10.1006/bbrc.1997.6800. View

16.

Pan W, Yu C, Hsuchou H, Kastin A . The role of cerebral vascular NFkappaB in LPS-induced inflammation: differential regulation of efflux transporter and transporting cytokine receptors. Cell Physiol Biochem. 2010; 25(6):623-30. PMC: 2910582. DOI: 10.1159/000315081. View

17.

Schwaninger M, Inta I, Herrmann O . NF-kappaB signalling in cerebral ischaemia. Biochem Soc Trans. 2006; 34(Pt 6):1291-4. DOI: 10.1042/BST0341291. View

18.

Quan N, Whiteside M, Herkenham M . Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide. Brain Res. 1998; 802(1-2):189-97. DOI: 10.1016/s0006-8993(98)00402-8. View

19.

Matsuda N, Hattori Y, Takahashi Y, Nishihira J, Jesmin S, Kobayashi M . Therapeutic effect of in vivo transfection of transcription factor decoy to NF-kappaB on septic lung in mice. Am J Physiol Lung Cell Mol Physiol. 2004; 287(6):L1248-55. DOI: 10.1152/ajplung.00164.2004. View

20.

Griesenbach U, Scheid P, Hillery E, de Martin R, Huang L, Geddes D . Anti-inflammatory gene therapy directed at the airway epithelium. Gene Ther. 2000; 7(4):306-13. DOI: 10.1038/sj.gt.3301078. View